Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 2
1979 4
1980 2
1981 1
1982 4
1983 4
1984 8
1985 13
1986 13
1987 19
1988 22
1989 74
1990 49
1991 56
1992 100
1993 112
1994 130
1995 145
1996 178
1997 215
1998 209
1999 243
2000 230
2001 253
2002 277
2003 318
2004 330
2005 278
2006 333
2007 320
2008 290
2009 256
2010 273
2011 249
2012 243
2013 242
2014 227
2015 251
2016 204
2017 183
2018 191
2019 163
2020 189
2021 151
Text availability
Article attribute
Article type
Publication date

Search Results

6,550 results
Results by year
Filters applied: . Clear all
Page 1
Paroxetine: a review.
Bourin M, Chue P, Guillon Y. Bourin M, et al. CNS Drug Rev. 2001 Spring;7(1):25-47. doi: 10.1111/j.1527-3458.2001.tb00189.x. CNS Drug Rev. 2001. PMID: 11420571 Free PMC article. Review.
Paroxetine is a potent and selective serotonin reuptake inhibitor (SSRI) with currently approved indications for the treatment of depression, obsessive-compulsive disorder, panic disorder and social phobia. ...Paroxetine exhibits some affinity for the muscarinic cho
Paroxetine is a potent and selective serotonin reuptake inhibitor (SSRI) with currently approved indications for the treatment of dep
Paroxetine in the treatment of premature ejaculation: a systematic review and meta-analysis.
Zhang D, Cheng Y, Wu K, Ma Q, Jiang J, Yan Z. Zhang D, et al. BMC Urol. 2019 Jan 3;19(1):2. doi: 10.1186/s12894-018-0431-7. BMC Urol. 2019. PMID: 30606186 Free PMC article.

However, there existed a high level of heterogeneity in the paroxetine vs. fluoxetine groups and the paroxetine vs. placebo groups. ...Paroxetine combined with tadalafil or behaviour therapy was more efficacious than paroxetine alone (all p < 0.05).

However, there existed a high level of heterogeneity in the paroxetine vs. fluoxetine groups and the paroxetine vs. placebo gr …
Effectiveness of Paroxetine for Poststroke Depression: A Meta-Analysis.
Li L, Han Z, Li L, Han L, Yan B. Li L, et al. J Stroke Cerebrovasc Dis. 2020 May;29(5):104664. doi: 10.1016/j.jstrokecerebrovasdis.2020.104664. Epub 2020 Feb 21. J Stroke Cerebrovasc Dis. 2020. PMID: 32093988 Review.
OBJECTIVE: The purpose of our study is to evaluate the efficacy of paroxetine in poststroke depression (PSD) patients by conducting a meta-analysis. ...Control treatment is more effective than paroxetine. No significant advantage was found with paroxetine. CO …
OBJECTIVE: The purpose of our study is to evaluate the efficacy of paroxetine in poststroke depression (PSD) patients by conducting a …
Paroxetine.
Tang SW, Helmeste D. Tang SW, et al. Expert Opin Pharmacother. 2008 Apr;9(5):787-94. doi: 10.1517/14656566.9.5.787. Expert Opin Pharmacother. 2008. PMID: 18345955 Review.
BACKGROUND: Paroxetine is a widely used antidepressant that has received attention regarding suicide risk in younger patients. ...RESULTS/CONCLUSION: Paroxetine is a serotonin re-uptake inhibitor with good selectivity and no significant active metabolites. ...
BACKGROUND: Paroxetine is a widely used antidepressant that has received attention regarding suicide risk in younger patients. ...RES …
Paroxetine hydrochloride.
Germann D, Ma G, Han F, Tikhomirova A. Germann D, et al. Profiles Drug Subst Excip Relat Methodol. 2013;38:367-406. doi: 10.1016/B978-0-12-407691-4.00008-3. Profiles Drug Subst Excip Relat Methodol. 2013. PMID: 23668408 Review.
Paroxetine hydrochloride (3S-trans)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-piperidine hydrochloride (or (-)-(3S,4R)-(4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)-phenoxy]methyl]piperidine hydrochloride), a phenylpiperidine derivative, is a selective serotoni
Paroxetine hydrochloride (3S-trans)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-piperidine hydrochloride (or (-)-(3S,4R)-(
Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial.
Jacobsen P, Zhong W, Nomikos G, Clayton A. Jacobsen P, et al. J Sex Med. 2019 Oct;16(10):1638-1649. doi: 10.1016/j.jsxm.2019.06.018. Epub 2019 Aug 9. J Sex Med. 2019. PMID: 31405765 Free article. Clinical Trial.
Non-compliance appeared to influence results, particularly the paroxetine and vortioxetine 20 mg arms. Paroxetine, but not vortioxetine, was associated with statistically significantly more TESD vs placebo. ...Assay sensitivity was demonstrated by statistically sign …
Non-compliance appeared to influence results, particularly the paroxetine and vortioxetine 20 mg arms. Paroxetine, but not vor …
Paroxetine controlled release.
Bang LM, Keating GM. Bang LM, et al. CNS Drugs. 2004;18(6):355-64; discussion 365-6. doi: 10.2165/00023210-200418060-00003. CNS Drugs. 2004. PMID: 15089103 Review.
A controlled-release (CR) formulation of the SSRI paroxetine has been developed. This CR formulation delays the release of paroxetine until the tablet has passed through the stomach; the drug is then released over 4-5 hours. ...Paroxetine CR was generally wel …
A controlled-release (CR) formulation of the SSRI paroxetine has been developed. This CR formulation delays the release of paroxet
A review of paroxetine for the treatment of vasomotor symptoms.
Slaton RM, Champion MN, Palmore KB. Slaton RM, et al. J Pharm Pract. 2015 Jun;28(3):266-74. doi: 10.1177/0897190014544785. Epub 2014 Aug 8. J Pharm Pract. 2015. PMID: 25107421 Review.
METHODS: Both PubMed and International Pharmaceutical Abstracts (IPA) were searched using the keywords hot flashes, vasomotor symptoms, menopause, and paroxetine. In PubMed, MeSH terms were used for paroxetine, menopause, and hot flashes. ...CONCLUSION: Paroxetin
METHODS: Both PubMed and International Pharmaceutical Abstracts (IPA) were searched using the keywords hot flashes, vasomotor symptoms, meno …
Paroxetine-related tremor.
Lai H, Tolat R. Lai H, et al. Geriatrics. 2005 Jul;60(7):18-20. Geriatrics. 2005. PMID: 16026177 Review. No abstract available.
Neuropharmacology of paroxetine.
Nemeroff CB, Owens MJ. Nemeroff CB, et al. Psychopharmacol Bull. 2003 Spring;37 Suppl 1:8-18. Psychopharmacol Bull. 2003. PMID: 14566196 Review.
The in vivo pharmacologic properties of paroxetine are well characterized, especially following acute administration. ...At usual clinical doses (ie, 20 mg/d), paroxetine is a potent and selective inhibitor of the SERT; however, at higher doses (ie, 40 mg/d), par
The in vivo pharmacologic properties of paroxetine are well characterized, especially following acute administration. ...At usual cli …
6,550 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page